The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...
Researchers from the Germans Trias i Pujol research institute (IGTP) have conducted a preclinical study on the effects of the drug empagliflozin, alone or in combination with sacubitril/valsartan, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results